



Disposals of own shares

Brussels (Belgium), 29 October 2021 – 20:00 (CEST) – regulated information

Disposal of own shares

In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB announces that, following exercises of stock options by members of its personnel, it has disposed of UCB shares OTC in view of deliveries of these shares to the relevant members of the personnel, within the framework of the Long Term Incentive Program of the UCB Group, as follows:

Date of transaction	Time	LTI Plan	Number of disposed UCB shares	Price
22 October 2021	11:25:40	Stock Option Plan 2012	250	€ 32,36
22 October 2021	11:59:56	Stock Option Plan 2013	100	€ 48,69
22 October 2021	12:18:40	Stock Option Plan 2012	1.400	€ 32,36
22 October 2021	15:00:05	Stock Option Plan 2013	100	€ 48,69
22 October 2021	16:06:38	Stock Option Plan 2014	400	€ 58,12
22 October 2021	16:08:55	Stock Option Plan 2015	700	€ 67,35
25 October 2021	09:20:02	Stock Option Plan 2012	2.200	€ 32,36
25 October 2021	10:25:06	Stock Option Plan 2012	100	€ 32,36
25 October 2021	15:31:42	Stock Option Plan 2018	2.160	€ 66,18
25 October 2021	16:12:16	Stock Option Plan 2017	600	€ 70,26
26 October 2021	11:18:00	Stock Option Plan 2017	400	€ 70,26
27 October 2021	15:44:01	Stock Option Plan 2012	200	€ 32,36
28 October 2021	15:32:01	Stock Option Plan 2012	200	€ 32,36
28 October 2021	15:32:42	Stock Option Plan 2012	500	€ 32,36
28 October 2021	15:32:52	Stock Option Plan 2012	2.250	€ 32,36
28 October 2021	15:37:34	Stock Option Plan 2012	1.350	€ 32,36
28 October 2021	15:37:34	Stock Option Plan 2013	100	€ 48,69
28 October 2021	15:37:34	Stock Option Plan 2013	100	€ 48,69
28 October 2021	15:37:34	Stock Option Plan 2012	1.100	€ 32,36

This press release is available on UCB SA/NV's website via the following [link](#).

Investor Relations

Antje Witte
Investor Relations, UCB

T +32 2 559 94 14,
antje.witte@ucb.com

Corporate Communications

Laurent Schots
Media Relations, UCB

T+32.2.559.92.64
laurent.schots@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 400 people in nearly 40 countries, the company generated revenue of € 5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news